MedicalResearch.com - Latest news, interviews, and insights into medical research, health and wellness, fitness and addiction.
Gastrointestinal Disease, Supplements / 08.07.2025

Please note: Bitters and other supplements are not FDA tested or approved. Some supplements including bitters can interfere with medications and/or cause side effects.  Bitters may relieve, but in some individuals, worsen symptoms so their use must be monitored by your health care provider.  Do not delay seeking medical attention for medical concerns by taking bitters without medical advice. A serious medical condition should be ruled out before considering supplements or bitters for your symptoms. Acid reflux is a widespread condition, affecting millions worldwide. Many turn to medications, but natural remedies like digestive bitters may offer effective relief by addressing the root causes of reflux rather than simply masking symptoms. In this article, we explore how digestive bitters can help manage acid reflux naturally.

What Are Digestive Bitters?

Digestive bitters are herbal preparations designed to stimulate digestion by activating bitter taste receptors on the tongue and throughout the digestive tract. Traditionally used in herbal medicine, common bitter herbs include gentian, dandelion, artichoke, and chamomile. These herbs support digestion by increasing digestive secretions and improving overall gastrointestinal motility. (more…)
Author Interviews, Gastrointestinal Disease, Hepatitis - Liver Disease / 13.05.2025

MedicalResearch.com discussion with: Dr. Bertus Eksteen PhD, MBChB, FRCP Founder of the Calgary PSC Clinic Member of the Calgary Liver Unit and the Southern Alberta Liver Transplant Clinic Aspen Woods Clinic Calgary, Canada Primary sclerosing cholangitis (PSC) is a liver disease characterized by progressive inflammation and scarring of the bile ducts. PSC still has no known cause or cure and often leads to liver failure or cancer. For patients and clinicians, the lack of answers is deeply frustrating. But that's beginning to change. Thanks to genetic research, we’re uncovering clues about PSC’s origins—and why it behaves differently from patient to patient. By learning more about the genomic underpinnings of PSC, researchers can create new treatment targets, devise risk profiles for early diagnosis, and even develop better clinical tools for detecting the disease in its earliest stages.  And that path forward doesn’t just start with new treatments — it begins in the lab.

Genetic Clues to PSC Onset

PSC isn't directly inherited, but genetics likely play a significant role in determining who develops the disease. Several immune-related gene variations, particularly those related to the human leukocyte antigen (HLA) complex, have increased the risks of developing PSC.  These variations don’t cause PSC on their own— researchers believe they interact with intestinal bacteria and other environmental factors, prompting the immune system to launch an attack on the bile ducts. Understanding these genetic foundations provides a roadmap for following this disease very early. Instead of reacting to symptoms, we can start asking why specific people are predisposed in the first place. That insight is key to prevention and long-term disease management. (more…)
Author Interviews, Cancer Research, Gastrointestinal Disease / 07.05.2025

MedicalResearch.com Interview with: Mohamed Tausif Siddiqui, MD The study’s lead author and a Gastroenterology fellow Cleveland Clinic. MedicalResearch.com: What is the background for this study? Response: Our study looked at how the stage of gastric cancer diagnosis has changed over the past two decades in the U.S., using national SEER data. Gastric cancer has long been a challenge because it’s often diagnosed late, when treatment options are limited and survival rates are poor. But with advancements in endoscopic technology—like high-definition imaging, narrow-band imaging, and endoscopic ultrasound—we wanted to see if these tools were making a difference in catching cancers earlier. (more…)
Author Interviews, Cancer Research, Colon Cancer, Gastrointestinal Disease, HPV / 07.05.2025

MedicalResearch.com Interview with: Ashley Robinson, MD, lead author Second-year internal medicine resident Advocate Lutheran General Hospital MedicalResearch.com: What is the background for this study? Response: Briefly, anal cancer makes up around 1% of gastrointestinal cancers and more than 90% of all anal cancers are caused by chronic human papillomavirus or HPV infections. In previous research, it has been noted that women over the age of 65 have rates that were increasing more than other groups and myself along with my colleagues and the principal investigator of this project, Dr. Eli Ehrenpreis, wanted to further characterize these findings, looking into more specific details of these previously noted trends. Using data from a public database ran by the National Cancer Institute called the Surveillance, Epidemiology and End Results program, also known as SEER, and their statistical analysis software, SEER*Stat, we analyzed anal cancer incidence trends, looking at differences between sex, age, and ethnicity in order to further identify specific groups that have more rapidly increasing rates than others. (more…)
Author Interviews, Gastrointestinal Disease, Hepatitis - Liver Disease, Weight Research / 07.05.2025

MedicalResearch.com Interview with: Dr. Katilyn Gernhard DO Internal Medicine Resident Allegheny Health Network Pittsburgh MedicalResearch.com: What is the background for this study? Response: The background for this study is the steadily rising prevalence of obesity in the United States, which has been accompanied by an increase in related comorbid conditions, including Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD). Bariatric surgery and GLP-1 receptor agonists are two commonly used treatment options to address obesity and its associated complications. While both have demonstrated benefits in weight loss and metabolic improvement, there has been limited direct comparison of their effectiveness specifically in patients with MASLD. Our study aimed to address this gap by comparing clinical outcomes in patients with MASLD treated with GLP-1 receptor agonists versus those treated with bariatric surgery. (more…)
Author Interviews, Gastrointestinal Disease / 07.05.2025

MedicalResearch.com Interview with: Dr. Simon Steenson PhD Postdoctoral Research Associate Department of Nutritional Sciences King’s College London MedicalResearch.com: What is the background for this study? Response: Chronic constipation is something that can be embarrassing, but it affects 1 in 10 people globally. It has a big impact on people’s quality of life and treating constipation has substantial costs for the healthcare system. Dried fruits are recommended for managing constipation, but there are very few studies that have actually tested whether following this advice is helpful. To fill this gap in our knowledge, we completed the largest clinical trial to date to see whether dried fruits and fruit juices could benefit constipation symptoms.  (more…)
Author Interviews, Colon Cancer, Gastrointestinal Disease, Race/Ethnic Diversity / 04.05.2025

MedicalResearch.com Interview with: Douglas Corley, MD, PhD Chief Research Officer, The Permanente Medical Group Kaiser Permanente, Northern California MedicalResearch.com: What is the background for this study? Response: Kaiser Permanente Northern California (KPNC) is an integrated health care system that designs and implements population-based programs that support cancer prevention and early detection. In 2006, KPNC began to implement a comprehensive colorectal cancer screening program with the goal of increasing member screening rates, preventing colorectal cancer through polyp removal, and reducing cancer mortality. The initiative identifies whether screening-eligible KPNC members are up to date with their colorectal cancer screening test by either a colonoscopy or by stool-based tests, such as a fecal immunochemical testing (FIT) kit. If they are not up to date with screening, it mails them a FIT kit for at-home testing. Members can also choose other options for colorectal cancer screening, such as a colonoscopy, through their physician. (more…)
Author Interviews, Gastrointestinal Disease, Genetic Research, Hepatitis - Liver Disease / 25.04.2025

MedicalResearch.com Interview with: Ashley Jowell, MD, Internal Medicine Resident Physician Duke University   Cynthia Moylan, MD Associate Professor of Medicine, Division of Gastroenterology Duke University Health System       MedicalResearch.com: What is the background for this study? Response: Metabolic dysfunction can lead to several health problems including metabolic dysfunction associated steatotic liver disease (MASLD), is driven by different factors, including: a person’s behavioral or lifestyle factors, environmental factors, and genetics. Limited research exists regarding genetic , epigenetic, or other factors that might impact development of metabolic dysfunction and MASLD. Our group has previously shown that alterations in DNA methylation (a type of epigenetic change), identifiable both in liver tissue and in blood, associate with MASLD and its progression to more severe liver disease.  Whether DNA methylation that impacts imprinted gene expression also associates with metabolic dysfunction and MASLD risk remains largely unknown. In this project, we explored imprinted genes: imprinting is a normal process that regulates genes by silencing one parental copy (either the maternal or the paternal) so that only one copy is expressed. Imprinting is an important biological process for development and has a disproportionate impact on disease  - in fact, imprinted genes are hypothesized to affect 1-6% of the human genome. We sought to explore how altered DNA methylation of imprint control regions (ICRs) that help ‘control’ these imprinted genes might impact development of metabolic dysfunction in children (and hence potentially even in adults).
Gastrointestinal Disease / 19.03.2025

Please consult your health care provider for specific recommendations regarding your digestive health.  This post is for informational purposes only and not specific medical advice. Do not delay medical attention based on information discussed here. Our digestive system is essential for overall health, yet millions experience gastrointestinal disorders each year. Issues like acid reflux, peptic ulcers, and inflammatory bowel disease are becoming more common. When left undiagnosed or untreated, these conditions can lead to severe complications, impacting daily life and long-term well-being. Endoscopy has become an essential tool in diagnosing GI disorders. In this blog post, we’ll talk about endoscopy in managing GI disorders.  However, if you’re experiencing persistent digestive issues, always search for an endoscopy specialist near me on Google to get an accurate diagnosis. They can offer tailored treatment options, ensuring better outcomes and improved quality of life. (more…)
Author Interviews, Gastrointestinal Disease / 11.02.2025

MedicalResearch.com Interview with: Arun B. Jesudian, MD Associate Professor of Clinical Medicine Medicine Weill Cornell Medical Center Transplant hepatologist at NewYork-Presbyterian/Weill Cornell Medical Center MedicalResearch.com: What is the background for this study? Response: In recent years, the demand for gastroenterologists continues to increase due to an aging population, increase in the prevalence of gastrointestinal and hepatology diseases, updates in screening and surveillance recommendations, and advances in therapeutic techniques. In this study, we set out to examine geographic distributions of gastroenterologists in the United States. MedicalResearch.com: What are the main findings? Response:  We found that on a national level, over 80% of the population lives within 25 miles of the closest gastroenterologist. However, 2,183 (69%) of the US counties do not have a practicing gastroenterologist, and 454 of the 1,167 metropolitan counties in the US do not have a gastroenterologist. Additionally, gastroenterologists in non-metropolitan counties tend to be older, with almost a third over the age of 65. (more…)
Gastrointestinal Disease, Supplements / 02.01.2025

Please note: Supplements are generally not FDA tested or approved. Some supplements can interfere with medications and/or cause side effects. Do not delay seeking medical attention for medical concerns by taking supplements without medical advice. Please discuss any and all supplements you take with your health care provider and be sure to follow your provider’s recommendations for your prostate and overall health. Supplements should not be given to children, breast feeding or pregnant women without the specific advice or your medical provider.  In addition some supplements, including berberine may interfere with other medications and prescription drugs. Please do not ignore new or continuing gastrointestinal symptoms, as they may indicate a more serious condition including ulcers, inflammatory bowel disease, genitourinary issues and cancer. See your health care provider for specific medical advice. When it comes to feeling your best, gut health is often the missing piece of the puzzle. Your gut isn’t just responsible for digesting food—it plays a role in everything from energy levels to immunity and even mental health. If you’ve been dealing with issues like bloating, irregular digestion, or low energy, it might be time to give your gut some extra attention. The good news is that you don’t need drastic measures to see results. With these five simple steps, you can naturally revitalize your gut health and improve your overall well-being.

1. Include Gut-Friendly Supplements

Supplements are a simple yet effective way to give your gut the boost it needs. While diet and lifestyle changes are crucial, adding targeted supplements can speed up the process of restoring balance to your gut microbiome. One supplement to consider is berberine, a natural compound with powerful benefits for gut health. Berberine works by reducing harmful bacteria in the gut while encouraging the growth of beneficial bacteria. This makes it a potential option for improving your gut's overall environment. If you’re considering berberine, Lakeview Pharmacy offers Berberine XL, an option that’s designed for maximum absorption. Unlike other berberine products, Berberine XL is purported to be formulated for enhanced absorption, so you get the most out of every dose. Berberine benefits may extend beyond gut health, too—it’s thought to support metabolic health, reduce inflammation, and more.  Just remember, supplements work best when paired with other healthy habits. Berberine should not be taken by pregnant or nursing women, women who are planning to become pregnant or children. See your health care provider for specific medical advice. (more…)
Gastrointestinal Disease, Microbiome, Probiotics, Supplements, Weight Research / 03.12.2024

Editor's note:  Please consult with your health care provider before using any supplements including probiotics. Side effects are uncommon but may occur. The connection between the gut and the brain is one of the most fascinating areas of research in recent years, with scientists uncovering how the microbiome—the trillions of microorganisms residing in our digestive system—can affect not just our digestion and immune system but also our feelings of hunger and satiety. As the science behind the gut-brain axis continues to unfold, it’s becoming increasingly clear that the health of our gut microbiome plays a pivotal role in regulating appetite, food intake, and body weight. Understanding the intricate relationship between gut health and appetite regulation has profound implications for combating obesity, overeating, and eating-related disorders. In this article, we’ll explore how the microbiome influences hunger, the role it plays in appetite regulation, and what you can do to optimize gut health for better control over your hunger and eating habits. We will also look at products which aim to support a healthy microbiome and improve overall well-being.

The Gut-Brain Axis: A Two-Way Communication

The gut-brain axis refers to the bidirectional communication between the gastrointestinal system (gut) and the brain. This connection is facilitated by the vagus nerve, immune pathways, and hormones, which allow the gut and brain to send signals back and forth. Recent research has shown that gut bacteria play a significant role in this communication, influencing not only digestion but also emotions, mental health, and, importantly, appetite regulation. The microbiome, composed of bacteria, viruses, fungi, and other microorganisms, affects the brain’s perception of hunger and fullness through the production of various chemicals, including neurotransmitters, hormones, and metabolites. These signals impact brain regions that control appetite, cravings, and food intake. (more…)
Gastrointestinal Disease, Legal-Malpractice, Pediatrics / 25.10.2024

  As parents, we always want the best for our children. This is especially true when it comes to their nutrition and overall health. That's why choosing the right baby formula is crucial in ensuring that our little ones receive the necessary nutrients for healthy growth and development. Unfortunately, not all baby formulas on the market are safe and effective. In fact, there have been cases where certain brands of baby formula have caused serious health issues in infants, leading to lawsuits against the manufacturers. NEC baby formula lawsuit lawyers help parents hold the responsible parties accountable for their actions and secure compensation. (more…)
Gastrointestinal Disease / 01.10.2024

Editors' note:  Be sure to follow up with recommended colonoscopy examinations.  If you are having bowel or rectal symptoms,  consult your health care provider before relying on home remedies.  When you're in the grip of hemorrhoid pain, relief can't come soon enough. It’s a common misconception that hemorrhoids are untreatable. However, there are numerous strategies you can employ to prevent and manage hemorrhoids, offering a glimmer of hope and empowerment in your journey to wellness. Hemorrhoids, depending on their position, can cause cases of bleeding, itching, soreness, or pain. Internal hemorrhoids lead to painless bleeding, while external hemorrhoids lead to pain. Below are the five tips that can assist in reducing hemorrhoid discomfort.

(more…)

Gastrointestinal Disease / 26.09.2024

Digestive disorders are far more common than many people realize, affecting around 40 million individuals in the US. Despite how widespread these conditions are, many people ignore the early signs, dismissing them as minor inconveniences. Unfortunately, what may seem like a little discomfort can often be a warning of a more significant health issue waiting to escalate. The key to preventing these issues from spiraling into long-term complications is recognizing the early signs. Many people don’t realize that digestive disorders, when caught early, can often be managed or even reversed with the right treatment plan. By ignoring symptoms like bloating, heartburn, or abdominal pain, we risk allowing our bodies to suffer silently, which could lead to more serious conditions. This article will help you guide you through the early signs of digestive disorders, helping you identify when it’s time to seek medical advice. (more…)
Gastrointestinal Disease, Nutrition / 24.06.2024

Crohn's disease is a type of inflammatory bowel disease. It causes inflammation in the digestive tract, which can lead to severe symptoms. The inflammation often spreads deep into the layers of affected bowel tissue. Crohn's disease can be painful and sometimes may lead to life-threatening complications. abdominal-pain-crohns_pexels-sora-shimazaki-5938358 Symptoms of Crohn's Disease Symptoms of Crohn's disease vary from mild to severe. Common symptoms include diarrhea, fever, fatigue, abdominal pain and cramping. People with Crohn's disease might also experience blood in their stool, mouth sores, reduced appetite and weight loss. The disease can affect different parts of the digestive tract in different people. The symptoms can change over time, with periods of severe symptoms (flares) and periods of no or mild symptoms (remission). Causes and Risk Factors The exact cause of Crohn's disease remains unknown. However, several factors may contribute to its development. These include immune system malfunctions, genetics and environmental factors. Crohn's disease tends to run in families, suggesting a genetic link. Smoking increases the risk of developing the disease and can make symptoms worse. People living in urban areas or industrialized countries have a higher risk, possibly due to diet and lifestyle factors. (more…)
Author Interviews, Colon Cancer, Gastrointestinal Disease, Immunotherapy / 04.06.2024

MedicalResearch.com Interview with: Steven H. Itzkowitz, MD, FACP, FACG, AGAF Professor of Medicine and Oncological Sciences Director of the GI Fellowship Program Icahn School of Medicine at Mount Sinai MedicalResearch.com: What is the background for this study? What are the main findings? Response: This study looked at patients with inflammatory bowel disease (IBD) who had a history of cancer in the past 5 years and asked whether the medications they received for their IBD might have affected their rates of getting future cancer (new or recurrent cancers). Because many of the medicines that are used to treat IBD can affect the immune system in various ways, there has been concern that the medicines might predispose to subsequent cancers. We found that patients who received immunosuppressive medications had a numerically increased risk of subsequent cancer, this was not statistically higher than those who had not been exposed to these medications. While previous studies have looked at this question retrospectively, this is the first report that analyzed this issue prospectively using individuals from the United States.  Moreover, this study represents a multi-institutional collaboration among gastroenterologists at most of the major NYC healthcare systems. (more…)
Author Interviews, Cost of Health Care, Gastrointestinal Disease, Health Care Systems / 20.05.2024

MedicalResearch.com Interview with: Laura Targownik, MD Lead author and Clinician-Investigator Mount Sinai Hospital in Toronto Departmental Division Director, Gastroenterology and Hepatology University of Toronto MedicalResearch.com: What is the background for this study? Was there a difference in the types of patients or need for surgery seen by the female/male physicians? Response: The background for this study is that there is an emerging body of literature that having a female physician leads to better patient outcomes in many health care settings, especially amongst patients undergoing surgery or being admitted to hospital.  However, this has not previously been evaluated in gastroenterology.  Female and male gastroenterologists may have different styles of practice on average, and this potentially could lead to differences in how patients engage with the health care system following an initial assessment. (more…)
Addiction, Author Interviews, Gastrointestinal Disease, Opiods / 03.02.2024

MedicalResearch.com Interview with: Joshua D. Madera, MD Department of Medical Education Geisinger Commonwealth School of Medicine Scranton PA What is the background for this study? Response: The US population continues to be drastically impacted by the opioid epidemic, with opioid-related deaths significantly increased compared to European countries. While prescription opioid distribution has gradually declined since its peak in 2011 [1], the rate of opioid prescriptions remains increased compared to 2000. Furthermore, there is considerable interstate variability in opioid distribution across the US. Identifying patterns in this variability may guide public health efforts to reduce opioid-related harms. Therefore, the primary objective of this study [2] from Geisinger Commonwealth School of Medicine was to explore variations in production quotas and state-level distribution of ten prescription opioids between 2010 and 2019. (more…)
Author Interviews, Brigham & Women's - Harvard, Gastrointestinal Disease, Obstructive Sleep Apnea, Technology / 18.11.2023

MedicalResearch.com Interview with: Giovanni Traverso MD PhD Karl Van Tassel (1925) Career Development Professor Department of Mechanical Engineering Koch Institute of Integrative Cancer Research Division of Gastroenterology Brigham and Women’s Hospital Harvard Medical School, Boston, MA, USA   MedicalResearch.com: What is the background for this study? Response: I think its always important to acknowledge that this is a big team effort.  We have the teams from MIT, Celero Systems, West Virgnia University (WVU) and Brigham and Women’s Hospital (BWH) all working together on this.   For this study, Celero prototyped the devices that we tested in pre-clinical (Swine) models and in a first-in-human study with the team at WVU. Our lab focuses on the development of ingestible devices for drug delivery and sensing and these have informed the development of these efforts as you can see. MedicalResearch.com: What types of vital signs are measurable in this fashion? Response: Heart rate and respiratory rate. (more…)
Author Interviews, Eli Lilly, Gastrointestinal Disease / 03.11.2023

MedicalResearch.com Interview with: Lotus Mallbris, M.D., Ph.D., Senior Vice President of Immunology Development Eli Lilly MedicalResearch.com: Would you briefly describe the condition of Crohn's disease and who is most susceptible to this disease? Response: Crohn's disease is a form of inflammatory bowel disease (IBD) that can cause systemic inflammation manifested as abdominal pain, diarrhea, fever and weight loss. It can lead to intestinal obstruction, fibrosis and other complications. Approximately 900,000 patients in the U.S. and 1 million patients in Europe are currently suffering from Crohn’s disease, and 70% of those have moderate to severe disease. Although the majority of patients are started on conventional therapy such as corticosteroids and immunomodulators, many will unfortunately progress to having moderate to severe disease. Furthermore, current therapies to treat Crohn’s disease often fail to achieve remission for a majority of patients, and of the patients who do achieve remission, a substantial proportion lose it within the first year. (more…)
Author Interviews, Eli Lilly, Gastrointestinal Disease, NEJM / 02.11.2023

MedicalResearch.com Interview with: Marla C. Dubinsky, MD Professor of Pediatrics and Medicine Icahn School of Medicine at Mount Sinai Co- director, Susan and Leonard Feinstein IBD Clinical Center Mount Sinai Health System MedicalResearch.com: What is the background for this study? Would you briefly describe the condition of UC? Response: Lucent 1 and Lucent 2 were the induction and maintenance registration trials studying the efficacy and safety of mirikizumab in patients 18 years and older with moderate to severely active ulcerative colitis. Mirikizumab is a monoclonal antibody targeting the p19 subunit of IL23. Lucent-3 is the open label extension arm for those meeting inclusion criteria after completing Lucent 2. This study evaluated the long term efficacy and safety of mirikizumab in patients with ulcerative colitis who completed a total of 104 weeks of active mirikizumab treatment. Ulcerative colitis is a chronic incurable inflammatory condition of colon. Common symptoms include diarrhea, blood in the stool, abdominal cramping and bowel urgency. Bowel urgency is one of the most burdensome symptoms that a patient with you could experience. (more…)
Author Interviews, Biomarkers, Gastrointestinal Disease / 16.08.2023

MedicalResearch.com Interview with: Daniel L. Worthley MBBS (Hons), PhD, MPH, FRACP, AGAF Gastroenterologist Associate Professor University of Adelaide MedicalResearch.com: What is the background for this study? Response: Cells are revolutionising healthcare, from modern faecal microbial transplantation in the gut to CAR-T cells fighting cancers, life healing life. Some aspects of cellular care are so entrenched in medicine that they are almost overlooked for the miraculous cellular therapies that they are, such as stem cell transplantation to treat haematological malignancies and, of course, in vitro fertilization, life creating life. Modern medicine is slowly, but surely, pivoting from pills to cells. Professor Siddhartha Mukherjeee, oncologist, scientist, and author, provides a beautiful thesis of this in his book Song of the Cell and in his TED talk on the cellular revolution in medicine (https://youtu.be/qG_YmIPFO68?feature=shared). I was lucky enough to have trained with Sid as a post-doc at Columbia and this concept was really drummed into me. But, as a gastroenterologist, perhaps it was the bacterial cells, rather than the blood cells, that had most to offer in the management of bowel disorders? Around the same time, Professors Jeff Hasty, Tal Danino and Omar Din from UC San Diego had been inventing and publishing, in my opinion, the best bacterial engineering work that has ever been produced to specifically target cancer. I remember when we first reviewed their 2016 Nature paper in our lab meeting (https://www.nature.com/articles/nature18930#citeas), it was like – “We gotta meet these guys!”. Through Tal, who was by then, working at Columbia, I was introduced to Jeff and I attended his lab meeting back in 2019. That was where our project began after a lab meeting in La Jolla. Rob Cooper had presented his work on horizontal gene transfer. Everything that comes out of Jeff’s lab is both practical and reproducible but also beautiful. Beautiful in a scientific self-evident way that instantly communicates the purpose, approach and outcomes of an experiment. Rob’s presentation that day was a case-in-point. Rob was studying genes and gene transfer in bacteria (see part of Rob’s fascinating presentation here, https://youtu.be/5nBsRF-BsA8?feature=shared). Genes are the fundamental unit of heredity and gene transfer (or inheritance) the process by which genes are passed from one cell to another. Genes may be inherited vertically when one cell replicates its DNA and divides into two, now separate, cells (reproduction). Genes are the stuff, and vertical gene transfer is the process, by which you receive your mother’s laugh and your father’s eyebrows. Genes may also, however, be inherited horizontally when DNA is passed between unrelated cells, outside of parent to offspring inheritance. Horizontal gene transfer is quite common in the microbial world. Certain bacteria can salvage genes from cell-free DNA found within its environment. This sweeping up of cell-free DNA, into a cell, is called natural competence. So, competent bacteria can sample their nearby environment and, in doing so, acquire genes that may provide a selective advantage to that cell. Like cellular panning for flecks of gold in a stream. After Rob’s presentation, Jeff, Rob and I started to discuss the possibilities. If bacteria can take up DNA, and cancer is defined genetically by a change in its DNA then, theoretically, bacteria could be engineered to detect cancer. Colorectal cancer seemed a logical proof of concept as the colorectal lumen is full of microbes and, in the setting of cancer, full of tumour DNA.  When a biophysicist, a scientist and a gastroenterologist walk into a bar, after a lab meeting, this is what can happen! Professor Susi Woods and Dr Josephine Wright, superb cancer scientists from Adelaide, Australia, were quickly recruited in as essential founding members of the group. We all got to work. Australian and US grants, lots of experiments, early morning Zoom calls across the Pacific, inventing new animal models and approaches, i.e. a many year, iterative process of design-build-test-learn, that got us all to where we are now. (more…)
Author Interviews, Gastrointestinal Disease, Immunotherapy / 17.05.2023

MedicalResearch.com Interview with: Marla Dubinsky, M.D. Professor of Pediatrics and Medicine Co-director of the Susan and Leonard Feinstein IBD Clinical Center Chief of the Division of Pediatric Gastroenterology and Nutrition Icahn School of Medicine at Mount Sinai     MedicalResearch.com: What is the background for this study? How does MIRIKIZUMAB differ from other medications for UC? Response: This is a phase 2 study to assess the PK (pharamcokinetics), safety and efficacy of mirikizumab in pediatric ulcerative colitis (UC). Mirikizumab is a humanized monoclonal antibody that specifically binds to the p19 subunit of interleukin-23, a key inflammatory mediator in inflammatory bowel disease. (more…)
Author Interviews, Diabetes, Gastrointestinal Disease / 04.05.2023

MedicalResearch.com Interview with: Celine B. E. Busch, Research Associate Gastroenterology and Hepatology Standard PhD Candidate Dr. Jacques Bergman Professor, Gastroenterology and Hepatology Amsterdam UMC MedicalResearch.com: What is the background for this study? Would you describe the ReCET procedure? Response: Currently more than 400 million people worldwide have type 2 diabetes (T2D) and these numbers are rapidly increasing. At the moment there is no treatment option available that effectively treats the root cause of T2D, i.e. insulin resistance, the increasing loss of response to our body’s own insulin. T2D is generally treated with drug therapy, yet drug therapy can be expensive, requires the patient to take their drugs every day, and at best “controls” the disease without actually resolving it. Despite the availability of many T2D drugs, less than 50% of all T2D have adequately controlled blood glucose levels. The duodenum (the first part of the small bowel, immediately distal to the stomach) has proven to play a crucial role in glucose homeostasis in T2D. We know from bariatric surgery, that bypassing the duodenum by an Roux-en-Y Gastric Bypass has an immediate and profound effect on T2D by improving the sensitivity to the body’s own insulin resistance. However, performing invasive bariatric surgery for many T2D is not feasible. But we can reach the duodenum easily via upper GI endoscopy. ReCET is a single endoscopic procedure, performed under deep sedation. The ReCET catheter is advanced next to the scope, and once it is placed in the duodenum the flex circuit is unfolded until it touches the full circumference of the duodenum. The flex circuit contains the electrodes that create a pulsed electric field which “electroporates” the cells. Electroporation irreversibly makes small, that cause the cell to die of natural cell death, or apoptosis. This process can be precisely titrated for its depth of damage and does not generate heat thus avoiding damage to deeper wall layers, a major hurdle for standard endoscopic ablation techniques. The ReCET procedure lasts about 60 minutes to treat a 10-15 cm segment of the duodenum. The procedure does not cause significant side-effects and patients are discharged the same day. (more…)
Author Interviews, Gastrointestinal Disease / 17.03.2023

MedicalResearch.com Interview with: Richard E. Moses, D.O., J.D. Gastroenterologist, Associate Vice President, Mirikizumab Indication Lead Global Medical Affairs, Eli Lilly and Company MedicalResearch.com: What is the background for this study? Would you briefly describe how mirikizumab works in UC?  Response: First, this study specifically evaluated mirikizumab, a humanized IgG4 monoclonal antibody that selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of UC. Regulatory decisions for mirikizumab as a potential treatment for adults with moderately to severely active UC in the U.S., E.U and other countries around the world are expected in 2023. If approved, mirikizumab has the potential to be the only UC treatment that selectively targets the p19 subunit of IL-23. Gastroenterologists today benefit from having data from a range of endpoints, which can help them determine appropriate treatment options depending on their specific patients' needs and symptoms. In addition to clinical response and clinical remission – which are often used to determine the effectiveness of a treatment – we can also use combined endpoints like histologic-endoscopic mucosal improvement (which gauges remission and treatment effectiveness), histologic-endoscopic mucosal remission (the reduction of underlying inflammation visible endoscopically) and inflammatory biomarkers faecal calprotectin (fCal) and C-reactive protein (CRP) to inform our treatment strategies. This analysis focused on patients treated with mirikizumab from the induction study who received intravenous mirikizumab every 4 weeks until Week 12 (LUCENT-1), and patients who responded to mirikizumab during 12-week induction period who were re-randomized for the maintenance period, receiving subcutaneous mirikizumab every four weeks up to Week 40 (LUCENT-2) for 52 weeks of continuous treatment. This study explored the relationship between achieving histologic-endoscopic mucosal improvement (HEMI), histologic-endoscopic mucosal remission (HEMR) and improvement of biomarkers fCal and CRP levels at Weeks 12 and 52. (more…)
Author Interviews, Gastrointestinal Disease, Mental Health Research / 08.02.2023

MedicalResearch.com Interview with: Yuan, Zhongshang PhD Department of Biostatistics School of Public Health Shandong University Jinan, Shandong, China What is the background for this study? Response: Comorbidities and genetic correlations between gastrointestinal tract diseases and psychiatric disorders have been widely reported, with the gut-brain axis (GBA) hypothesized as a potential biological basis. However, it is unclear the degree to which the shared genetic determinants contribute to these associations underlying GBA. (more…)
Author Interviews, Cancer Research, Gastrointestinal Disease / 20.05.2022

MedicalResearch.com Interview with: Bashar J. Qumseya, MD, MPH, FASGE Associate Professor of Medicine Chief of Endoscopy University of Florida, Gainesville  MedicalResearch.com:  What is the background for this study?  What are the main findings? Response: Barrett’s esophagus (BE), is a premalignant condition that can lead to esophageal cancer (called esophageal adenocarcinoma). Both diseases have historically been thought of as diseases of elderly white males. While both diseases have been on the rise in the elderly population, we noted that some cancers are becoming more common at younger ages. We wanted to see if the prevalence of BE and EC are increasing at younger ages.  We aimed to assess the prevalence of BE in and EAC based on age group in a large database of over 5 million patients.  (more…)